MILAN, July 17, 2025 /PRNewswire/ -- A recently published five-year pharmacovigilance study confirms the excellent safety profile of a fixed-dose combination…
June 21, 2025 18:00 ET | Source: BioAge Labs, Inc. Treatment with apelin receptor agonist enhanced glycemic control and demonstrated…
VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- 1317229 B.C. Ltd. (“131” or the “Company”) and Launchit Solutions Inc.…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an…
U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE SINGAPORE, June 2, 2025 /PRNewswire/ -- Hotel101 Global Holdings Corp. ("Hotel101" or…
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant…
Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of…
TROPION-Lung02 and TROPION-Lung04 phase 1b results support combination of Daiichi Sankyo and AstraZeneca’s DATROWAY with immunotherapy as first-line treatment for…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1…